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Context: Nonclassic congenital lipoid adrenal hyperplasia (lipoid CAH) is a recently recognized
disorder caused by mutations in the steroidogenic acute regulatory protein (StAR) that retain
partial function. Affected individuals can present with a phenotype of late onset adrenal insuffi-
ciency with only mild or minimally disordered sexual development.
Objectives: The aim was to delineate the clinical spectrum of StAR mutations and correlate phe-
notype with StAR activity.
Patients:Fourpatientshadnonclassic/atypicallipoidCAH.Adrenalinsufficiencywasmanifestedat
birth in two patients and at 11 months and 4 yr in the other two. Three were 46,XY with under-
developed genitalia.
Methods:TheStARgenewassequenced,mutationswererecreatedinexpressionvectors,andStAR
activity was measured as pregnenolone production in COS-1 cells cotransfected with the choles-
terol side-chain cleavage system. StAR mutants were expressed as N-62 StAR in bacteria, and
purified proteins were tested for activity with isolated steroidogenic mitochondria and for cho-
lesterol-binding capacity.
Results: DNA sequencing identified mutations on all alleles. Missense mutations were R188C,
G221D, L260P, and F267S; we also tested R192C described by others. The respective activities of
R188C, R192C, G221D, L260P, and F267S were 8.0, 39.4, 2.4, 3.1, and 6.1% of wild-type in trans-
fected cells, and 12.8, 54.8, 6.3, 1.8, and 9.5% with isolated mitochondria. Cholesterol binding
capacities of R188C, R192C, G221D, L260P, and F267S were 6.7, 55.3, 10.2, 4.6, and 20.9%. These
data are correlated to the three-dimensional structure of StAR.
Conclusions: There is a broad clinical spectrum of StAR mutations; StAR activities in vitro correlate
well with clinical phenotypes. (J Clin Endocrinol Metab 95: 3352–3359, 2010)
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ongenital lipoid adrenal hyperplasia (lipoid CAH) is
the most severe form of congenital adrenal hyper-
plasia (CAH) in which the synthesis of all adrenal and
gonadal steroid hormones is impaired. Early clinical hor-
monal studies and incubations of affected tissue in vitro
with various precursors identified a defect in the conver-
sion of cholesterol to pregnenolone, so that the disorder
was initially called “20,22 desmolase deficiency” because
itwasthoughttoresultfromadefectintheenzymesystem
converting cholesterol to pregnenolone. This enzyme was
later identified as mitochondrial P450scc. For a review of
the early history of lipoid CAH, see Ref. 1. However, the
P450scc gene is normal in lipoid CAH (2, 3), and in 1995
itwasfoundthatlipoidCAHresultsfrommutationsinthe
gene encoding the steroidogenic acute regulatory protein
(StAR)(4,5).StARfacilitatesthemovementofcholesterol
into mitochondria, where it is converted to pregnenolone
by P450scc (6). Patients with classic lipoid CAH usually
present with adrenal failure and salt wasting, beginning
within the first few months of life, and have female exter-
nal genitalia irrespective of genetic sex (7). Until the de-
scriptionofnonclassiclipoidCAHin2006,onlyonemin-
imally virilized 46,XY female had been reported (8).
Nonclassic lipoid CAH is a recently recognized disorder
caused by StAR mutations that retain partial activity (9).
Affected individuals can present with adrenal insuffi-
ciency resembling nonautoimmune Addison disease with
only mildly disordered sexual development or normal de-
velopment with hypergonadotropic hypogonadism (9,
10). More than 40 StAR mutations causing classic lipoid
CAHhavebeendescribed(4,7,8,11),butveryfewpartial
loss-of-functionmutationshavebeenreported(8–10).We
describe four patients with nonclassic or atypical lipoid
CAH, identify their StAR mutations, and characterize the
activities of the mutants to explore genotype/phenotype
correlations.
Patients and Methods
Patient 1
A 46,XY phenotypic male from a consanguineous Thai fam-
ilyhadanuneventfulbirthandhadtwofebrileseizuresduringhis
first2yroflife,butnolaboratorydataareavailable.Hewasfirst
evaluated at Chulalongkorn University Hospital at age 4 yr for
progressivepigmentation.Hisolderbrotherhadhadprogressive
hyperpigmentation and at 3 yr had fever, convulsions, and sud-
den unexplained death. The patient had descended testes, a
stretched penile length of 3.5 cm and glandular hypospadias.
Hormonal data (Table 1) showed unmeasurable cortisol unre-
sponsive to cosyntropin, low dehydroepiandrosterone (DHEA)
sulfate,andgrosslyelevatedACTH.Plasmareninactivity(PRA)
was9.62ng/ml/h(normalrange,1.0–6.5),aldosteronewas25.5
ng/dl (normal range, 3–35), and the electrolytes were normal,
indicating a subtle defect in mineralocorticoid secretion. Ab-
T
A
B
L
E
1
.
C
l
i
n
i
c
a
l
a
n
d
b
i
o
c
h
e
m
i
c
a
l
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
p
a
t
i
e
n
t
s
P
a
t
i
e
n
t
1
R
1
8
8
C
P
a
t
i
e
n
t
2
L
2
6
0
P
/
F
2
6
7
S
P
a
t
i
e
n
t
3
R
1
8
8
C
/
W
2
5
0
X
P
a
t
i
e
n
t
4
G
2
2
1
D
P
a
t
i
e
n
t
5
(
R
e
f
.
1
0
)
R
1
9
2
C
C
o
u
n
t
r
y
o
f
o
r
i
g
i
n
T
h
a
i
l
a
n
d
U
n
i
t
e
d
S
t
a
t
e
s
S
w
i
t
z
e
r
l
a
n
d
N
e
p
a
l
L
e
b
a
n
o
n
K
a
r
y
o
t
y
p
e
4
6
,
X
Y
4
6
,
X
Y
4
6
,
X
Y
4
6
,
X
X
4
6
,
X
Y
A
g
e
a
t
i
n
v
e
s
t
i
g
a
t
i
o
n
4
y
r
N
e
w
b
o
r
n
3
.
5
m
o
n
t
h
s
1
2
y
r
5
y
r
G
e
n
i
t
a
l
i
a
N
o
r
m
a
l
m
a
l
e
,
g
l
a
n
d
u
l
a
r
h
y
p
o
s
p
a
d
i
a
s
M
i
c
r
o
p
e
n
i
s
,
s
m
a
l
l
t
e
s
t
e
s
,
s
e
v
e
r
e
h
y
p
o
s
p
a
d
i
a
s
M
i
c
r
o
p
e
n
i
s
,
c
r
y
p
t
o
r
c
h
i
d
i
s
m
N
o
r
m
a
l
f
e
m
a
l
e
N
o
r
m
a
l
m
a
l
e
P
r
e
s
e
n
t
a
t
i
o
n
P
i
g
m
e
n
t
a
t
i
o
n
A
m
b
i
g
u
o
u
s
g
e
n
i
t
a
l
i
a
P
i
g
m
e
n
t
a
t
i
o
n
,
a
m
b
i
g
u
o
u
s
g
e
n
i
t
a
l
i
a
A
d
r
e
n
a
l
c
r
i
s
i
s
P
i
g
m
e
n
t
a
t
i
o
n
A
d
r
e
n
a
l
i
m
a
g
i
n
g
N
o
r
m
a
l
U
S
N
o
r
m
a
l
C
T
N
D
N
o
r
m
a
l
M
R
I
N
D
A
C
T
H
(
p
g
/
m
l
)

1
2
5
0
5
6
0
5
4
9
7
2
0
7
0

2
2
5
C
o
r
t
i
s
o
l
( 
g
/
d
l
)
B
a
s
a
l
0
.
1
8
5
.
3

1
0
.
6
P
e
a
k
0
.
1
1
1
N
D
N
D
N
D
P
R
A
(
n
g
/
m
l
/
h
)
9
.
6
2
9
5
N
D
1
5
m
U
/
l
i
t
e
r
(
3
–
4
0
)
5
.
8
2
A
l
d
o
s
t
e
r
o
n
e
(
n
g
/
d
l
)
2
5
.
5
1
4
N
D

2
.
5
1
.
2
L
H
(
I
U
/
l
i
t
e
r
)
N
D
1
5
.
2
7
.
6
N
D
2
1
.
9
F
S
H
(
I
U
/
l
i
t
e
r
)
N
D
1
6
.
7
5
.
0
N
D
5
0
.
4
T
r
e
a
t
m
e
n
t
P
r
e
d
n
i
s
o
n
e
H
y
d
r
o
c
o
r
t
i
s
o
n
e
,
f
l
u
d
r
o
c
o
r
t
i
s
o
n
e
H
y
d
r
o
c
o
r
t
i
s
o
n
e
,
f
l
u
d
r
o
c
o
r
t
i
s
o
n
e
H
y
d
r
o
c
o
r
t
i
s
o
n
e
,
f
l
u
d
r
o
c
o
r
t
i
s
o
n
e
H
y
d
r
o
c
o
r
t
i
s
o
n
e
C
T
,
C
o
m
p
u
t
e
d
t
o
m
o
g
r
a
p
h
y
;
M
R
I
,
m
a
g
n
e
t
i
c
r
e
s
o
n
a
n
c
e
i
m
a
g
i
n
g
;
N
D
,
n
o
t
d
o
n
e
;
U
S
,
u
l
t
r
a
s
o
u
n
d
.
C
o
n
v
e
r
s
i
o
n
t
o
S
y
s
t
e
m
I
n
t
e
r
n
a
t
i
o
n
a
l
u
n
i
t
s
:
A
C
T
H
,
p
i
c
o
g
r
a
m
s
p
e
r
m
i
l
l
i
l
i
t
e
r

0
.
2
2
f
o
r
p
i
c
o
m
o
l
e
s
p
e
r
l
i
t
e
r
;
c
o
r
t
i
s
o
l
,
m
i
c
r
o
g
r
a
m
s
p
e
r
d
e
c
i
l
i
t
e
r

2
7
.
6
f
o
r
n
a
n
o
m
o
l
e
s
p
e
r
l
i
t
e
r
;
P
R
A
,
n
a
n
o
g
r
a
m
s
p
e
r
m
i
l
l
i
l
i
t
e
r
p
e
r
h
o
u
r

0
.
7
7
f
o
r
p
i
c
o
m
o
l
e
s
p
e
r
m
i
l
l
i
l
i
t
e
r
p
e
r
h
o
u
r
;
a
l
d
o
s
t
e
r
o
n
e
,
n
a
n
o
g
r
a
m
s
p
e
r
d
e
c
i
l
i
t
e
r

2
7
.
7
f
o
r
p
i
c
o
m
o
l
e
s
p
e
r
l
i
t
e
r
.
J Clin Endocrinol Metab, July 2010, 95(7):3352–3359 jcem.endojournals.org 3353dominal ultrasound showed a normal-size right adrenal, but the
left adrenal was not seen. The patient was treated with pred-
nisoneindosesequivalenttohydrocortisone11–14mg/m
2/dand
remained well with normal electrolytes. Sequencing of the
ACTH receptor (MC2R), DAX1, and HSD3B2 genes was
normal.
Patient 2
A 27-yr-old 46,XY male was born at term with micropenis,
third-degree hypospadias, severe chordee, a hypoplastic scro-
tum,andpalpabletestes.Ahumanchorionicgonadotropinstim-
ulation test at 3–7 d of life failed to increase progesterone, 17-
hydroxyprogesterone (17OHP), DHEA, androstenedione, and
testosterone.Hiselectrolyteswerenormal,andhedidnotrequire
supplementalsteroidsduringtheneonatalperiod.Atage10wk,
cortisol was 8.5 g/dl, but his ACTH was 560 pg/ml (normal,
10–50), indicating partially compensated adrenal insufficiency.
His aldosterone was 14 ng/dl (normal, 5–90), and his PRA was
95ng/ml/h(normal,2.3–37).Duringaninsulintolerancetest,his
basalcortisolwas21g/dl,butitfailedtorisefurther;anACTH
stimulation test failed to increase urinary 17-ketosteroids or se-
rum levels of progesterone, 17OHP, cortisol, and DHEA. An
abdominal computed tomography scan at age 12 wk did not
show adrenal enlargement. The patient was diagnosed with
“partial20,22desmolasedeficiency”andstartedonlifelongglu-
cocorticoid and mineralocorticoid replacement therapy. During
his first 2 yr, he had several adrenal crises, including at least one
with documented salt-wasting (Na, 124 mEq/liter; and K, 6.1
mEq/liter), associated with respiratory, gastrointestinal, or skin
infectionsandrequiringbriefhospitalizationsforparenteralglu-
cocorticoids. He had normal growth and development and un-
derwent a two-stage genital repair at age 2. He did not undergo
puberty, and testosterone treatment was initiated during ado-
lescence. When seen at the University of Pennsylvania at age 25,
he was 185 cm tall, weighed 157 kg, and had hyperpigmented
skin, 5-ml testes bilaterally, and a penile length of 4 cm. His
0800 h cortisol before taking hydrocortisone was less than 5
g/dl, with ACTH 5911 pg/ml, total testosterone 78 ng/dl, LH
15.2 IU/liter, and FH 16.7 IU/liter. The parents declined genetic
testing. His sister is unaffected, and her carrier status is
unknown.
Patient 3
A 46,XY Serbian male infant presented at age 3.5 months
having had prolonged neonatal jaundice. He had severe gener-
alized hyperpigmentation, cryptorchidism, micropenis, but no
hypospadias.WhenevaluatedatUniversityChildren’sHospital,
Zurich, Switzerland, his sodium and potassium were normal,
cortisolwas5.3g/dl,andACTHwas5497pg/ml.Aldosterone
and PRA were not measured; testosterone was 29 ng/dl (normal
upto232ng/dl).Hewastreatedwithhydrocortisoneandfludro-
cortisone and received three testosterone injections (25 mg) be-
tween4and6monthsofagewithgoodpenileresponseto3.5cm.
He underwent right orchiopexy at 2 yr. When he was 8.5 yr old,
his height was 134.5 cm (50th–75th percentile), and weight was
39.8 kg (97th percentile) while receiving hydrocortisone 20.8
mg/m
2/d and fludrocortisone 0.1 mg/d. He remained well with
normalelectrolytesbuthadahistoryofsalt-craving.Sequencing
of DAX1 and SF1 was normal.
Patient 4
A 15-yr-old, 46,XX Nepalese girl had recently moved to the
United Kingdom and was referred to the Portsmouth Hospital
withadiagnosisof“CAH”.Shehadfirstpresentedat11months
of age with adrenal crisis including vomiting and dehydration
and had subsequently been treated with hydrocortisone and
fludrocortisone, but no hormonal data are available. She re-
ported menarche at 12 yr of age and regular menstruation, but
progesterone at d 22 of the cycle was low at 0.2 nmol/liter, in-
dicatinganovulatorycycles.HerACTHwas2070pg/ml,andshe
hadunmeasurablecortisol(1g/dl),aldosterone(2.5ng/dl),
testosterone (10 ng/dl), 17OHP (60 ng/dl), androstenedione
(30 ng/dl), and DHEA sulfate (15 g/dl) (Table 1). Her
plasmaandurinesteroidprofileswerecompatiblewithcomplete
adrenal insufficiency. A magnetic resonance imaging scan
showed normal-sized adrenals.
Mutation analysis, mutagenesis, and transfection
With informed consent, leukocyte genomic DNA was ex-
tracted, and the seven exons of the StAR gene were amplified by
PCR and sequenced using previously described oligonucleotides
and amplification conditions (12). Mutant full-length StAR
cDNA expression vectors (13) were generated by PCR-based,
site-directed mutagenesis (primers are shown in Table 2) and
verifiedbydirectsequencing.ThePCRconditionswere:95Cfor
30 sec, 16 cycles of 95 C for 30 sec, 55 C for 1 min, and 68 C for
18 min. Nonsteroidogenic monkey kidney COS-1 cells were
grown in DMEM supplemented with 10% fetal calf serum and
antibioticsat37Cinahumidified5%CO2incubator.Cellswere
divided into 12-well plates (Falcon; BD Biosciences, Lincoln
Park, NJ) and cotransfected using Effectene (QIAGEN,
Valencia, CA) at approximately 50% confluence. Cotransfec-
tionsweredonewithapCMV-StARexpressionvectorandtheF2
plasmid expressing a fusion protein of the cholesterol side-chain
cleavage system (H2N-P450scc-adrenodoxin reductase-adreno-
doxin-COOH) (14). To monitor transfection efficiency, cells
were also cotransfected with 5 ng of Renilla luciferase reporter
plasmid(pRL-CMV)(Promega,Madison,WI)perwell.Culture
media were collected 48 h later, and pregnenolone production
was measured by enzyme immunoassay (ALPCO Diagnostics,
TABLE 2. Oligonucleotide sequences for site-directed mutagenesis
Name Sequence NCBI accession no.; location
R188C TTTGTGAGCGTGTGCTGTGCCAAGC NM_000349; 826
R192C GCGCTGTGCCAAGTGCCGAGGCTCCAC NM_000349; 838
G221D AGGGCGGAGCACGATCCCACTTGCATG NM_000349; 926
L260P ATCAACCAGGTCCCGTCCCAGACCCAG NM_000349; 1043
F267S ACCCAGGTGGATTCTGCCAACCACCTG NM_000349; 1064
Boldface and underlined bases indicate a nucleotide change. The numbering of nucleotides is based on the NCBI human StAR cDNA sequence
NM_000349. The numbering of the amino acid residues is based on the NCBI human StAR protein reference sequence NP_000340.2.
3354 Sahakitrungruang et al. Partial Loss-of-Function StAR Mutations J Clin Endocrinol Metab, July 2010, 95(7):3352–3359Salem, NH). The sensitivity of this assay is 5.4 ng/dl. Data are
presented as the mean  SEM for at least three independent ex-
periments, each performed in triplicate.
Preparation of vectors and proteins and in vitro
biochemical assays
Each StAR mutation was inserted into the sequence of N-62
StAR in the modified pTWIN1 intein expression plasmid (15).
The plasmids were individually transformed into Escherichia
coli BL21DE3. StAR expression was induced with 0.5 mM iso-
propyl--D-thiogalactopyranoside at 28 C for 6–8 h. Bacteria
were lysed by sonication and cleared of debris; the supernatant
wasloadedontochitin-bindingcolumns(NewEnglandBiolabs,
Ipswich, MA), washed, and eluted according to the manufac-
turer’s recommendations. The N-62 StAR was collected and di-
alyzed against 300 mM NaCl, 20 mM Tris (pH 7.5) (15, 16).
Wild-type N-62 StAR was quantitated by the Bradford method,
and mutant proteins were quantitated with a standard curve of
wild-typeN-62StAR(Fig.1).Mitochondriawerepreparedfrom
mouseMA-10Leydigcellsasdescribed(13).PurifiedN-62StAR
proteins (5 M) were added to mitochondria (5 g of Bradford
protein)in50lof125mMKCl,5mMMgCl2,10m MKH2PO4,
25mMHEPES(pH7.4),250ng/mltrilostane,100MGTP,and
10 mM isocitrate, and incubated for 1 h; conversion of mito-
chondrial cholesterol to pregnenolone was measured by enzyme
immunoassay, as above.
Cholesterol binding assay
Cholesterol binding capacity was measured by mixing purified
N-62 StAR proteins (1 M) in PBS with various amounts of fluo-
rescent 22-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino-23,24-
bisnor-5-cholen-3-ol) (NBD-cholesterol) (Invitrogen, Carlsbad,
CA) in 96-well plates (final volume, 100 l). The samples were
incubated1ha t3 7Ca n dexcited at 480 nm, and steady-state
fluorescence emission at 540 nm (cutoff, 515 nm) was monitored
withaSpectraMaxM2microplatereader(MolecularDevicesInc.,
Sunnyvale, CA) (16).
Results
StAR mutations
Patient1washomozygousforthemutation5033CT,
changing arginine 188 to cysteine (R188C) (NCBI genomic
DNAreferencesequenceNG_011827.1,andStARprotein
reference sequence NP_000340.2) (17, 18). Homozygous
R188C was found in one of the initial patients with non-
classiclipoidCAH(9)andinfourfamiliesreportedinRef.
10. Patient 2 was a compound heterozygote for
6732TC, changing leucine 260 to proline (L260P); and
6753TC,changingphenylalanine267toserine(F267S).
L260P was described in Swiss patients with classic lipoid
CAH (19); F267S is a novel mutation. Patient 3 was
compound heterozygous for R188C and tryptophan
250 stop mutation (W250X). Homozygous W250X
was previously found in a Serbian 46,XY phenotypic fe-
malewithclassiclipoidCAH(20).Patient4washomozy-
gous for the novel mutation 5780GA, changing glycine
to aspartic acid (G221D).
Functional studies of the StAR mutants in
transfected cells
Westudiedthefunctionalconsequencesofthefourmis-
sense StAR mutants identified here and the mutation
R192C recently found in a family with nonclassic lipoid
CAH, but which had not been characterized functionally
(10).WecotransfectednonsteroidogenicCOS-1cellswith
either wild-type or mutant StAR and a vector expressing
the F2 fusion of the cholesterol side chain cleavage system
(14) and compared the amount of pregnenolone pro-
duced. An empty vector was used as a negative control,
and 22R-hydroxycholesterol, which bypasses the action
of StAR and thus indicates the maximal enzymatic capac-
ityoftheP450sccsystem(4,7,13)wasaddedasapositive
control.Usingendogenouscellularcholesterolandcho-
lesterol in the serum in the culture media as substrate,
COS-1 cells expressing F2 and wild-type StAR made
1917  422 ng/dl of pregnenolone, whereas cells trans-
fected with the empty vector produced a low level of
pregnenolone(2311ng/dl),indicatingthepresenceof
StAR-independent steroidogenesis. The R188C mutant
produced 175  8 ng/dl of pregnenolone, whereas the
G221D, L260P, and F267S mutants generated 68  17,
82  23, and 138  16 ng/dl, respectively. By contrast,
R192C produced substantially more pregnenolone at
FIG. 1. Quantification of StAR protein. Top panel, The indicated
amounts of purified wild-type N-62 StAR protein and mutant purified
N-62 StAR proteins were separated by 12% SDS-PAGE. The band
intensity was measured by Scion Image software. Bottom panel, The
standard curve of StAR protein. The amount of mutant N-62 StAR
proteins was plotted against its band intensity.
J Clin Endocrinol Metab, July 2010, 95(7):3352–3359 jcem.endojournals.org 3355769  169 ng/dl. When the background of StAR-inde-
pendent steroidogenesis is subtracted, the R188C,
R192C, G221D, L260P, and F267S mutants had 8.0,
39.4,2.4,3.1,and6.1%ofwild-typeactivity,respectively
(Fig.2A).Inthisassay,pregnenoloneproductioninallfive
StAR mutations was significantly higher than vector con-
trol (P  0.05).
Activities of purified StAR proteins with
steroidogenic mitochondria
To assess the activities of StAR mutants in a cell-free
system,weexpressedN-62StARproteinusingaself-splic-
ing bacterial intein system. Purified N-62 StAR protein
(Fig. 1) was added to mitochondria isolated from mouse
Leydig MA-10 cells, and StAR activity was measured as
pregnenolone produced from endogenous mitochondrial
cholesterol. In this assay, wild-type N-62 StAR elicited
1816  293 ng/dl pregnenolone, and the buffer control
lackingStARproduced263.337.7ng/dlpregnenolone,
indicatingalevelofStAR-independentsteroidogenesisap-
proximately 14% of the StAR-induced level. After sub-
tracting the buffer control, the R188C, R192C, G221D,
L260P, and F267S mutants elicited 12.8, 54.8, 6.3, 1.8,
and 9.5% of wild-type activity, respectively (Fig. 2B). In
comparison to the buffer control, R188C (P  0.0001),
R192C(P0.0001),G221D(P0.02),andF267S(P
0.002) elicited significantly more pregnenolone, whereas
the activity of L260P was not different from the buffer
paired (two-tailed Student’s t test; P  0.57).
Cholesterol-binding capacity of the mutant StAR
proteins
Purified recombinant proteins were combined with
various concentrations of NBD-cholesterol, and choles-
terolbindingwasmeasuredfluorometrically.Thebinding
of fluorescent NBD-cholesterol to StAR is very similar to
thatof[
14C]cholesterol;hence,thisreadilymeasuredform
ofcholesterolisappropriateformeasuringthecholesterol
bindingcapacityofStAR(16).Aftersubtractingthebuffer
control,themaximalcholesterolbindingcapacityofthe
R188C, R192C, G221D, L260P, and F267S mutants
was 6.7, 55.3, 10.2, 4.6, and 20.9% of the wild-type
value (Fig. 2C). Thus, the impaired activity of the mu-
tantsgenerallycorrelatedwiththeirimpairedcapacities
to bind cholesterol.
Discussion
StAR moves cholesterol from the outer mitochondrial
membrane(OMM)totheinnermitochondrialmembrane,
thus providing the cholesterol substrate for steroidogen-
esis(4,21).StARexertsthisactionontheOMM(13,22),
where it must undergo a conformational change that re-
sults from its interaction with protonated OMM phos-
pholipids (15, 23–25). The essential role of StAR in ad-
renal and gonadal steroidogenesis was established by
finding recessive, loss-of-function mutations of StAR in
FIG. 2. Activities of StAR mutants. A, Activity of full-length StAR in
whole cells. COS-1 cells were cotransfected with expression vectors for
the cholesterol side-chain cleavage system (F2) and either wild-type
(WT) or mutant StAR, and pregnenolone was measured 48 h later by
immunoassay. The StAR-independent substrate 22(R)-hydroxycholes-
terol (22R-OH) was added to the cell culture media to determine the
maximum steroidogenic capacity of the cells. Data are expressed as
the mean  SEM from at least three independent experiments,
each performed in triplicate. B, Activity of isolated N-62 StAR on
mitochondria in vitro. Purified proteins were added to mitochondria
from steroidogenic mouse MA-10 Leydig cells, and pregnenolone
production from endogenous mitochondrial cholesterol was measured.
Data are expressed as mean  SEM from four experiments, each
performed in duplicate. C, Cholesterol binding assay. Binding of
various concentrations of NBD-cholesterol by wild-type and mutant
StAR was measured by fluorescence; control is buffer without protein.
Data are expressed as mean  SEM for three experiments, each
performed in triplicate.
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known exclusively as a very severe disorder of steroido-
genesischaracterizedbygreatlydiminishedorabsentsyn-
thesis of all adrenal and gonadal steroids (26). Affected
individuals with classic lipoid CAH are phenotypically
female and have severe salt loss in early infancy. None-
theless, affected 46,XX females spontaneously develop
secondary sex characteristics and experience cyclical vag-
inal bleeding, but the cycles are anovulatory, and the pa-
tientshaveprogressivehypergonadotropichypogonadism
later in life (12, 27). These unusual findings were ex-
plained by the two-hit model (7). In early lipoid CAH,
StAR-independent mechanisms can still move some cho-
lesterol into mitochondria, resulting in a low level of ste-
roidogenesis, and increased corticotropin secretion (first
hit).Overtime,lipiddropletsaccumulate,damagethecell,
and eventually destroy steroidogenic capacity (second
hit). In the ovary, follicular cells remain unstimulated and
thus undamaged until they are sequentially recruited in
monthlycyclesbeginningatpuberty.Bycontrast,thefetal
testicularLeydigcellsareaffectedearlyingestationdueto
stimulation by chorionic gonadotropin.
In 2006, Baker et al. described three children from two
families who presented with adrenal insufficiency at 2–4
yr of age; the males had normal genitalia. These patients
werehomozygousforStARmutationsV187MandR188C;
functional studies of these mutants showed that they re-
tainedapproximately20%ofwild-typeactivity(9).These
data delineated a new disorder, nonclassic lipoid CAH.
Later,Metherelletal.(10)reportedfivefamilieswithnon-
classiclipoidCAHwhohadinitiallybeenmisdiagnosedas
having familial glucocorticoid deficiency. Four families
carried R188C, and one carried R192C. All affected pro-
bands presented with Addisonian phenotypes at 2–7 yr of
age, but one affected male remained undiagnosed and
untreated until 58 yr of age (10). Several patients with
nonclassic StAR mutations have progressive hypergona-
dotropic hypogonadism and azoospermia, potentially
compromising fertility (10). Thus, identifying patients
with nonclassic lipoid CAH is important because, unlike
patients with familial glucocorticoid deficiency, they may
have compromised fertility and mild salt loss.
Althoughmassiveadrenalenlargementisaclassichall-
mark of lipoid CAH (26), this sign is not pathognomonic.
Small adrenals have been reported in patients with classic
lipoid CAH (11), and such enlargement has not been re-
ported in patients with nonclassic phenotypes (9, 10), al-
though hypoplastic adrenals with calcifications, suggest-
ing cirrhotic, end stage fat deposition, have been reported
(10). None of the patients in our study had evidence of
adrenalenlargementbyabdominalimaging.Similarly,pa-
tients with CYP11A1 mutations causing P450scc defi-
ciency, who have clinical manifestations that are indistin-
guishable from StAR mutations, have not been reported
withenlargedadrenals(28).Thus,inthesettingofadrenal
insufficiency, massively enlarged adrenals indicate classic
lipoid CAH; normal-sized adrenals cannot exclude it but
instead suggest P450scc deficiency or nonclassic lipoid
CAH.
StAR mutations have been described in many ethnic
groups but are common in Japan, Korea, and some iso-
lated populations (1, 7, 8, 19). The R188C mutation
found in our Thai patient has also been reported in pa-
tients from Canada, Jordan, India, and Pakistan (9, 10),
suggesting a recurrent mutation. StAR mutations in in-
tronic regions can also cause lipoid CAH (5, 29). Most
StAR missense mutations are found in the carboxy-termi-
nal 40% of the 285-amino acid StAR protein (1) and to-
tally eliminate StAR activity. Only five previously de-
scribed mutations were associated with residual StAR
activity in transfected COS-1 cells: V187M (22%) (9),
R188C (14%) (9), A218V (6%) (7), M225T (29%) (8),
andL275P(10%)(7).Again-of-functionStARmutation,
Q128R,hasbeenreportedrecentlyina46,XXphenotypic
female infant who had salt loss at 4 months, but the co-
existenceofhomozygousframeshiftnullmutationablated
all StAR activities, so the potential effect of the Q128R
mutationwasnotevidencedinthepatient(30).Themech-
anism by which this mutant gains function is unknown.
Themanifestationsandseverityofdiseasedifferedsub-
stantially in our patients. Patient 1, who had the mildest
phenotype, was homozygous for R188C. In our assays of
intracellular activity, mitochondrial activity, and choles-
terol-bindingcapacity,R188Cretained8,12.8,and6.7%
of wild-type activity, respectively; when we studied this
mutant previously, the values for these assays were 13.6,
17.7, and 21.0% (9). Hence, whereas there is some vari-
ability in these biochemical assays, it seems that 10–20%
of activity will dramatically alter the classic phenotype.
The report of the patient carrying R192C, which retained
about 50% of wild-type activity, indicated even milder
disease (10). By contrast, patient 2, carrying both F267S
(10% activity) and L260P (3% activity) had fairly se-
vere disease, as did patient 4, who was homozygous for
G221D (6% activity). Among the three assays we used,
the direct assays of StAR activity, rather than the choles-
terol-bindingassay,appeartoprovidethebestcorrelation
with the clinical phenotype. A disparity between the ac-
tivity assays and the binding assay is not surprising, be-
cause StAR mutation R182L was homozygous in patients
with classic lipoid CAH and lacked activity in functional
assays (7, 11) but retained normal capacity to bind cho-
lesterol, indicating that cholesterol binding is necessary
but not sufficient for StAR activity (16). Thus, there is a
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the clinical phenotypes.
The crystal structures of three proteins closely related
to StAR have been determined (31–33), permitting the
construction of reliable computational models of human
StAR (25, 34). StAR’s structure features a hydrophobic
pocketofthesizeandshapeneededtobindcholesterol;the
amphipathic C-terminal -helix (C-helix) forms the
“floor”ofthepocket,withhydrophobicresiduespointing
inward and hydrophilic residues pointing outward. The
structure shows no direct access to this pocket. Liposome
protection experiments show that only the C-terminal
-helix (C-helix) interacts with the OMM (25), and the
position of the C-helix is stabilized by a network of hy-
drogen bonds with the adjacent structures (25, 34). Mo-
lecular dynamics simulations indicate that interaction of
StAR with protonated phospholipids on the OMM dis-
rupts these hydrogen bonds, inducing a conformational
change(moltenglobuletransition),permittingtheC-helix
to swing open to allow the binding of cholesterol into the
sterolbindingpocketofStAR;consistentwiththismodel,
disulfide mutants that immobilize the C-helix but that do
notalterStAR’sconformationinterferewithStARactivity
and cholesterol binding (15, 35).
Many mutations that cause lipoid CAH, including
thoseidentifiedinthisstudy,arelocatedintheC-terminal
helix or elsewhere in the sterol-binding pocket. Leu260
and Phe267 are conserved hydrophobic residues in the
C-helix, forming part of the cholesterol-binding site.
Arg188andArg192lieinsheet6,andG221isintheloop
joining sheets 8 and 9, which contribute to the sterol-
binding pocket. Consistent with this, the reduced activity
ofthesemutantswasassociatedwithreducedcholesterol-
binding capacity. The mechanism by which StAR facili-
tates the movement of cholesterol into the mitochondrion
is incompletely understood, but it appears to involve sev-
eralotherproteinsontheOMM.Functionaldataindicate
thatthe18-kDaperipheralbenzodiazepinereceptor(PBR;
also called the mitochondrial translocator protein) must
be present for StAR to act (36), and homo-bifunctional
protein cross-linking data show that StAR comes into
closecontactwiththevoltage-dependentanionchannel-1
and with a phosphate-carrier protein on the OMM (37).
Additional data suggest that StAR participates in a large
macromolecular complex, which, in addition to StAR,
PBR,andvoltage-dependentanionchannel,includesPBR-
associated protein 7, protein kinase A regulatory subunit
I, and adenine nucleotide transporter (38, 39). Substan-
tial additional work is needed to delineate the role of each
of these proteins in mitochondrial cholesterol import; the
potential discovery of patients carrying mutations in any
of these could be most informative.
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